CMPS ▼ -0.1% - COMPASS Pathways plc $CMPS - Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training Compass Pathways selected Fluence to develop post-approval provider training for COMP360, its psilocybin therapy candidate. The modest decline suggests the market view this as a routine operational step rather than a significant catalyst, though the move indicates progress toward commercialization readiness if regulatory approval is obtained. 10-SEP-2026 08:02 AM ET